Company Filing History:
Years Active: 2013
Title: The Innovations of Erland Arning in Fabry Disease Research
Introduction
Erland Arning is a notable inventor based in Fort Worth, TX (US), recognized for his contributions to medical research, particularly in the field of Fabry disease. His innovative work focuses on the use of tetrahydrobiopterin as a therapeutic agent and biomarker for this rare genetic disorder.
Latest Patents
Arning holds a patent titled "Use of tetrahydrobiopterin as a marker and a therapeutic agent for Fabry disease." This patent discloses the use of blood and tissue markers to assess the metabolic status and risk of health complications in patients with Fabry disease. It also describes how tetrahydrobiopterin (BH4), along with its precursors and metabolites, can be utilized to monitor treatment efficacy in both animal models and human patients. Furthermore, the invention outlines BH4 therapy as a potential treatment option to prevent, slow, or reverse the vascular, cardiac, and renal manifestations associated with Fabry disease.
Career Highlights
Erland Arning is affiliated with the Baylor Research Institute, where he conducts significant research aimed at improving the lives of individuals affected by Fabry disease. His work has garnered attention for its potential to change treatment paradigms in this area of medicine.
Collaborations
Arning has collaborated with esteemed colleagues such as Raphael Schiffmann and Teodoro G Bottiglieri, contributing to a collective effort to advance understanding and treatment of Fabry disease.
Conclusion
Erland Arning's innovative research and patent contributions are pivotal in the ongoing fight against Fabry disease. His work not only enhances the understanding of this condition but also opens new avenues for effective treatment options.